Health

Add as a preferred source on Google

Avacta Reports Complete Responses for AVA6207 in Two Animal Tumor Models

The experimental drug produced responses in ovarian and lung cancer models, while cell studies found greater sensitivity in ATM-deficient cells.

Updated 2 min read
A researcher examines tumor samples in an oncology laboratory in Barcelona, Spain. (AI-generated image / EconoTimes)
A researcher examines tumor samples in an oncology laboratory in Barcelona, Spain. (AI-generated image / EconoTimes)

Avacta reported preclinical results for AVA6207, an experimental cancer drug, including complete responses in two animal tumor models; the findings identify specific models for further study but do not show whether the drug works in people.

The company said all animals in an ovarian cancer patient-derived xenograft model had complete responses. In a separate model using non-small cell lung cancer tumors, four of five animals had complete responses. The ovarian tumors were ATM-positive and SLFN11-low; the lung tumors had low levels of both, according to Avacta.

In cell studies, Avacta said AVA6207 reversed resistance associated with SLFN11 deficiency. ATM-deficient cells were about 10 times more sensitive to the candidate than ATM-positive or wild-type cells, the company said. These results concern the reported laboratory and animal models and do not establish activity across cancers with those biomarkers.

AVA6207 contains exatecan, a topoisomerase I inhibitor, and berzosertib, an ATR inhibitor. Avacta said the drug is designed to release both payloads after a single cleavage event involving fibroblast activation protein (FAP) in the tumor microenvironment.

The company also reported greater activity than Enhertu in a gastric cancer patient-derived xenograft model, but did not provide a numerical comparison. Avacta said it is evaluating potential biomarker-defined indications in colorectal, non-small cell lung, ovarian and esophageal squamous cell cancers.

Avacta said the data were presented Nov. 19 at the 38th EORTC-NCI-AACR Symposium in Barcelona. With payload selection complete, the company said it is beginning studies intended to support an investigational new drug application. It did not specify when clinical testing could begin.

Related articles

View all